基本信息
浏览量:2
职业迁徙
个人简介
Virginia Arechavala-Gomeza is an Ikerbasque Research Professor. She is the head of the "Nucleic Acids Therapeutics for Rare Diseases NAT-RD" Research group at Biocruces Bizkaia Health Research Institute and Chair of COST Action "Delivery of Antisense RNA ThERapeutics (DARTER).
Trained as a pharmacist ( University of the Basque Country, Spain, 1998), she completed her education with an MSc in Immunopharmacology (University of Strathclyde, Glasgow) and a PhD in the molecular basis of amyotrophic lateral sclerosis (King’s College London, 2005). As a postdoctoral researcher (Imperial College London and University College London), she participated and the first two clinical trials for eteplirsen, and in the preclinical development of this and other antisense oligonucleotides currently approved for the treatment of Duchenne muscular dystrophy.
Since 2013, thanks to a Miguel Servet Fellowship and a Marie Curie Career Integration grant, she leads the NAT-RD (previously Neuromuscular Disorders) research group at Biocruces Bizkaia Health Research Institute, a recently created institution that consolidates the research produced in the Basque health system. She was appointed as an Ikerbasque Research Professor in 2019 and her main interest is the development of better methods to evaluate candidate treatments for neuromuscular disorders, such as advanced therapies. Through the international network DARTER, (www.antisensera.eu, over 360 researchers in 31 countries), she aims to improve the delivery of oligonucleotide drugs to target tissues.
Prof Arechavala-Gomeza has authored many scientific publications (cited over 4000 times, with a third of them cited over 100 times). Publications include invited contributions, several book chapters, and an edited book. She serves in several Spanish and international grant review panels, has collaborated as an expert with the European Medicines Agency and, since 2020, is a member of the Basque Drug Research Ethics Committee (CEIm-E) which meets up twice a month.
Her group’s research funding comes from European, Spanish, and Basque institutional grants, as well as patient’s associations. As indicated before, she has contributed to the development of several approved orphan drugs, being one of her contributions the development of methodological tools to assess the efficacy these treatments (the “Arechavala-Gomeza method” and methods based on it have been used in the evaluation of several clinical trials). Her group has also optimised methods for preclinical screening of drugs in cell culture (myoblots) that has led to collaborations with companies to screen small molecules, and in 2019 was awarded with the “Ezkertze-excellence in research award” by the Cruces University Hospital. In 2019, Prof Arechavala-Gomeza participated in the creation of Miramoon Pharma, a spin-off company where she serves as a shareholder and member of the Scientific Advisory Board.
As well as presenting in over 50 international research meetings, Prof Arechavala-Gomeza actively participates in science communication activities in English and Spanish, many of which are easily accessible online. She is particularly interested in the accessibility of research results: she is involved in several activities to promote the publication of “negative” results (including editing a special issue in the subject), and is helping to plan a Basque institutional health repository.
Her role as a mentor was awarded in 2017 with the Outstanding Mentor Award by the Society of Spanish Researchers in UK. She has supervised many masters and degree research projects in the UK and in Spain, is currently supervising two predoctoral students and has served in many masters’ and thesis’ tribunals in Spain and abroad.
Prof Arechavala-Gomeza is a founding member of CERU/SRUK (Spanish researchers in the UK). As a female researcher and mother of two girls who took extensive maternity leave and worked part-time during her early postdoctoral years, she is very commited to promote the role of women in STEM and is member of several local and international networks in the field, as well as member of the equality committee at the IIS Biocruces Bizkaia, responsible for drafting the first Gender Equality Plan of the institution.
研究兴趣
论文共 72 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EUROPEAN JOURNAL OF HUMAN GENETICS (2023): 211-211
引用0浏览0引用
0
0
Alessia Cavazza,Ayal Hendel,Rasmus O. Bak,Paula Rı́o,Marc Güell,Duško Lainšček,Virginia Arechavala‐Gomeza,Ling Peng,Fatma Zehra Hapil, Joshua Harvey,Francisco G. Ortega,Coral González-Martínez,Carsten W. Lederer,Kasper Mikkelsen,Giedrius Gasiūnas,Nechama Kalter,Manuel A.F.V. Gonçalves, Jesper Petersen,Alejandro Garanto,Lluı́s Montoliu,Marcello Maresca,Stefan E. Seemann,Jan Gorodkin,Loubna Mazini, Rosario Sánchez,Juan R. Rodríguez-Madoz,Noelia Maldonado-Pérez,Torella Laura,Michael Schmueck‐Henneresse,Cristina Maccalli,Julian Grünewald,Gloria Carmona,Neli Kachamakova‐Trojanowska,Annarita Miccio,Francisco Martín,Giandomenico Turchiano, Toni Cathomen,Yonglun Luo,Shengdar Q. Tsai,Karim Benabdellah
Molecular therapy Nucleic acids (2023): 102066-102066
Nucleic acid therapeuticsno. 4 (2023): 238-247
bioRxiv (Cold Spring Harbor Laboratory) (2023)
A. López-Martínez,P. Soblechero-Martín,C. Catalli, A. Jauregui-Barrutia, S. Kapetanovic-Garcia,G. Nogales-Gadea,V. Arechavala-Gomeza
Neuromuscular Disorders (2022): S132-S133
RNA Therapeuticspp.121-137, (2022)
加载更多
作者统计
#Papers: 72
#Citation: 4090
H-Index: 23
G-Index: 63
Sociability: 6
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn